Search International and National Patent Collections
|1. (WO2018039490) USE OF GENOMIC SIGNATURES TO PREDICT RESPONSIVENESS OF PATIENTS WITH PROSTATE CANCER TO POST-OPERATIVE RADIATION THERAPY|
|Applicants:||GENOMEDX BIOSCIENCES, INC.
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
ASHAB, Hussam, Al-Deen
ZHAO, Shuang, G.
CHANG, S., Laura
FENG, Felix, Y.
|Title:||USE OF GENOMIC SIGNATURES TO PREDICT RESPONSIVENESS OF PATIENTS WITH PROSTATE CANCER TO POST-OPERATIVE RADIATION THERAPY|
Methods, compositions, and kits for identifying individuals who will be responsive to post-operative radiation therapy for treatment of prostate cancer are disclosed. In particular, the invention relates to a genomic signature based on expression levels of DNA Damage Repair genes that can be used to identify individuals likely to benefit from post-operative radiation therapy after a prostatectomy.